# Inverse Agonism of Cannabinoid Receptor Type 2 Confers Neuroprotection After Status Epileptics > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-receptor-type-2-anti-inflammatory-effects-se/ > **Published:** 2021-10-05T15:40:02-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:16:55-04:00 > **Clinical Summary:** Explore cannabinoid receptor type 2 anti-inflammatory effects that protect the brain following status epilepticus and reduce neuronal damage. --- When the brain is attacked by infections, microglia, the immune cells that reside inside and regulate inflammation in the brain, are activated and initiate inflammatory processes to destroy the foreign pathogens and protect neurons. However, when the inflammatory reaction is too powerful and long-lasting, increased neuronal excitability, lowered seizure threshold, and subsequently neural death may result. These events manifest as seizures in general, and status epilepticus in particular. Status epilepticus (SE) is a seizure that lasts for longer than 5 minutes or a series of continuous seizures where patients can’t recover in between. Cannabinoid receptor type 2 is widely expressed in microglia but not in neurons. Especially upon infection, microglia are activated to rapidly increase their expression of CB2. Therefore, compounds that bind to and change the activity of this receptor don’t affect the psychological state but may exert anti-inflammatory benefits to the brain. Pre-clinical research using rats has recently resulted in a drug candidate for SE. A blocker of the brain [CB2 receptor](https://cedclinic.com/s-caryophyllene-a-terpine-found-in-cannabis-demonstrates-therapeutic-potential-in-a-mouse-model-of-ms/), this compound has been demonstrated to decrease the inflammatory reactions in activated microglia and protect neurons from being damaged and killed in rat hippocampal tissues. In addition, transient treatment with this compound after an episode of SE subsequently reduced inflammation and prevented seizure, neuronal death, and behavioral impairments in lab rats when SE was induced again. These evidence support the hypothesis that targeting the [CB2 receptor](https://cedclinic.com/s-caryophyllene-a-terpine-found-in-cannabis-demonstrates-therapeutic-potential-in-a-mouse-model-of-ms/) represents an appealing therapeutic strategy to reduce [brain inflammation](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) and damage following prolonged seizures. [More access here](https://cedclinic.com/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [A Cannabinoid-Like Compound Modulates Neuronal Excitability, May Reduce Seizures](https://cedclinic.com/cannabinoid-like-compound-seizure-reduction/) Learn how cannabinoid-like compounds influence neuronal excitability and their potential to reduce seizures. [Read More](https://cedclinic.com/cannabinoid-like-compound-seizure-reduction/) [Gut cells prime T-cells to trigger brain inflammation in MS: Study](https://cedclinic.com/gut-brain-immune-axis-connection-ms-inflammation/) Discover the role of immune cells in [brain inflammation](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) and implications for neuroinflammatory conditions. [Explore Study](https://cedclinic.com/gut-brain-immune-axis-connection-ms-inflammation/) [Endocannabinoid System in Mental Health Treatment Research](https://cedclinic.com/endocannabinoid-system-mental-health-research/) Review current research on the endocannabinoid system's impact on [mental health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/) therapies. [Learn More](https://cedclinic.com/endocannabinoid-system-mental-health-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Inverse%20Agonism%20of%20Cannabinoid%20Receptor%20Type%202%20Confers%20Neuroprotection%20After%20Status%20Epileptics&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoid-receptor-type-2-anti-inflammatory-effects-se%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoid-receptor-type-2-anti-inflammatory-effects-se%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Inverse%20Agonism%20of%20Cannabinoid%20Receptor%20Type%202%20Confers%20Neuroprotection%20After%20Status%20Epileptics%20https%3A%2F%2Fcedclinic.com%2Fcannabinoid-receptor-type-2-anti-inflammatory-effects-se%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).